The present Invention relates to novel antibodies against Flcoiin-3, which antibodies inhibit complement activation. The invention further relates to the use of anti-Ficolin-3 antibodies in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to nucleic acid molecules encoding such antibodies, vectors and host cells used in the production of the antibodies.
